Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oxaprozin pharmacokinetics in the elderly.

D J Greenblatt, R Matlis, J M Scavone

    British Journal of Clinical Pharmacology
    |March 1, 1985
    PubMed
    Summary

    Oxaprozin, a nonsteroidal anti-inflammatory drug, is slowly absorbed and eliminated, with a mean half-life of 59 hours. Its pharmacokinetic profile suggests suitability for once or twice-daily dosing in healthy adults.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Response to diazepam in sons of alcoholics.

    Alcoholism, clinical and experimental research·1992
    Same author

    Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone.

    Brain research bulletin·1992
    Same author

    Mental illness, pharmacotherapy, and automobile operation: what is the risk?

    Journal of clinical psychopharmacology·1992
    Same author

    Bioavailability studies of drugs with nonlinear pharmacokinetics: I. Tracer dose AUC varies directly with serum concentration.

    Journal of clinical pharmacology·1992
    Same author

    Pharmacokinetics and preliminary observations of behavioral changes following administration of midazolam to dogs.

    Journal of veterinary pharmacology and therapeutics·1992
    Same author

    Fluoxetine impairs clearance of alprazolam but not of clonazepam.

    Clinical pharmacology and therapeutics·1992

    Area of Science:

    • Pharmacokinetics
    • Clinical Pharmacology
    • Geriatric Medicine

    Background:

    • Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) used for managing pain and inflammation.
    • Understanding the pharmacokinetic profile of oxaprozin is crucial for optimizing its therapeutic use, especially in diverse age groups.

    Purpose of the Study:

    • To investigate the pharmacokinetics of a single oral dose of oxaprozin in healthy adult volunteers.
    • To assess the influence of age and gender on oxaprozin's absorption, distribution, and elimination.

    Main Methods:

    • 42 healthy volunteers (aged 21-89 years) received a single 1200 mg oral dose of oxaprozin.
    • Plasma concentrations were measured using high-performance liquid chromatography (HPLC) over 14 days.
    • Key pharmacokinetic parameters including half-life, volume of distribution, and clearance were calculated.

    Related Experiment Videos

    Main Results:

    • Peak plasma concentrations were observed between 3-6 hours post-dose, indicating slow absorption.
    • The mean elimination half-life was 59 hours (range: 36-92 hours), signifying slow elimination.
    • Apparent volume of distribution decreased with age, and total clearance declined with age in men but not significantly in women.

    Conclusions:

    • Oxaprozin exhibits slow absorption and elimination, with a long half-life.
    • Age-related changes in body composition and gender-specific metabolic capacity influence oxaprozin pharmacokinetics.
    • The pharmacokinetic profile supports the potential for once or every-other-day dosing of oxaprozin.